TG Therapeutics rises after preliminary Q4 net product revenue tops estimates

TG Therapeutics

14/01/2025 12:40

** Shares of drugmaker TG Therapeutics  TGTX.O  rise 5.9% to
$29.31 premarket 
    ** Co forecasts preliminary Q4 net product revenue of $103.6
mln vs analysts' avg. est. of $97.69 mln - data compiled by LSEG
    ** Sees full-year 2024 net product revenue of $310 mln,
above est. of $304.1 mln
    ** TGTX expects to end 2024 with cash position of about $310
mln 
    ** Co forecasts 2025 total revenue of about $540 mln vs est.
of $549.5 mln 
    ** Up to last close, stock had risen 62.5% in past 12 months

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))